News

Chemtex builds biorefinery
Enlarge image

BusinessDenmarkItaly

Chemtex builds biorefinery

24.08.2012 - The US government will support Novozymes's partner Chemtex Inc. in its aim to construct a cellulosic ethanol plant in North Carolina by backing a US$99m loan.

The plant is expected to be located in Sampson County, North Carolina and produce 20 million gallons (76 million liters) of bioethanol per year from up to 600,000 tons of non-food grasses. The enzymes necessary for processing the biomass will be provided by Danish biotech company Novozymes (Baegsvaard). The construction is set to begin in late 2012. “Realising a commercial scale cellulosic ethanol plant in the United States and proving that it can produce cost competitive sustainable ethanol is an important milestone in the commercialisation process of advanced biofuels,” said Guido Ghisolfi, President of the Chemtex Group, which is a unit of the Italian chemical company Grupo Mossi & Ghisolfi.http://www.gruppomg.com/history.php?mi=201 

Slated to open in 2014, the plant will employ approximately 65 employees and indirectly generate 250 more jobs in the community, not including construction jobs. The feedstock will be grown on low productivity/marginal land that is in part being utilised as “spray fields” for the hog farming industry. Wilmington, North Carolina-based Chemtex received US$3.9m from the US Department of Agriculture in Junehttp://www.chemtex.com/templates/news_20120613.html to grow more than 4,000 acres of miscanthus and switchgrass, which will now be used as feedstock. Chemtex and Novozymes have already started a collaboration this April aimed at building the world’s first industrial plant for fermentation of second generation bioethanol from cheap straw feeds.

BusinessSwitzerlandUK

23.04.2014 In an effort to focus on key businesses, pharma giant Novartis is joining forces with long-time rival GlaxoSmithKline in a multi-billion Euro asset exchange and an OTC joint venture.

FinanceSwedenFrance

18.04.2014 Oxthera AB, a Swedish biopharma company with a focus on rare diseases, has gained a SEK70m cash injection to continue its clinical programme for primary hyperoxaluria.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)344.00 GBP12.6%
  • THERAMETRICS (CH)0.11 CHF10.0%
  • ACTIVE BIOTECH (S)35.60 SEK9.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • BAVARIAN NORDIC (D)13.63 EUR-6.4%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK73.5%
  • WILEX (D)0.81 EUR42.1%
  • E-THERAPEUTICS (UK)28.00 GBP40.0%

FLOP

  • CYTOS (CH)0.16 CHF-94.1%
  • BIONOR PHARMA (N)2.17 NOK-45.7%
  • IMMUNICUM AB (S)16.40 SEK-36.9%

TOP

  • SILENCE THERAPEUTICS (UK)257.25 GBP6174.4%
  • IXICO (UK)66.50 GBP737.5%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.16 CHF-96.1%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014